EC Pulmonology and Respiratory Medicine

Obesity is a civilization disease of the 21^st century, which is associated with excessive accumulation of fat tissue due to a positive energy balance. Obesity increases the risk of diseases such as: for hypertension, diabetes, obstructive sleep apnea. The impact of obesity on respiratory disorders is multifactorial. The distribution of body fat in obese people has a greater impact on the respiratory system than body weight or body mass index (BMI). Obstructive sleep apnea is one of the few diseases in which obesity may be both a cause of the disease and its consequence.

Sleep is one of the basic physiological needs and is an important element for the proper functioning of the body. Sleep deprivation significantly affects immune disorders, the development of insulin resistance, obesity and diabetes. This review focused on the analysis of available publications regarding the current treatment of obstructive sleep apnea and the possibilities offered by tirzepatide. According to current medical knowledge, weight loss is associated with a reduction in breathing disorders during sleep. Previous recommendations for the treatment of OSA focused mainly on symptomatic treatment and weight loss. Currently, it seems justified to include drugs that may affect the cause of the problem in the standard of treatment. Current research shows that tirzepatide is one of the GLP-1 and GIP analogues that effectively reduces the mass of fat tissue that accumulates in the neck and chest in the case of obstructive sleep apnea.

 Keywords: Obesity; Obstructive Sleep Apnea; Fat Tissue; BMI; Tirzepatide

1. Health topics. Obesity.
2. De Lorenzo., et al. “Why primary obesity is a disease?” Journal of Translational Medicine 1 (2019): 169.
3. Pi-Sunyer X. “The medical risks of obesity”. Postgraduate Medicine 6 (2009): 21-33.
4. Dixon AE and Peters U. “The effect of obesity on lung function”. Expert Review of Respiratory Medicine 9 (2018): 755-767.
5. Mafort TT., et al. “Obesity: systemic and pulmonary complications, biochemical abnormalities, and impairment of lung function”. Multidisciplinary Respiratory Medicine 11 (2016): 28.
6. Al Ghobain M. “The effect of obesity on spirometry tests among healthy non-smoking adults”. BMC Pulmonary Medicine 12 (2012): 10.
7. Bermúdez Barón N., et al. “Body mass index increase: a risk factor for forced expiratory volume in 1s decline for overweight and obese adults with asthma”. ERJ Open Research 4 (2022): 00110-2022.
8. Dixon AE and Peters U. “The effect of obesity on lung function”. Expert Review of Respiratory Medicine 9 (2018): 755-767.
9. Mafort TT., et al. “Obesity: systemic and pulmonary complications, biochemical abnormalities, and impairment of lung function”. Multidisciplinary Respiratory Medicine 11 (2016): 28.
10. Al Ghobain M. “The effect of obesity on spirometry tests among healthy non-smoking adults”. BMC Pulmonary Medicine 12 (2012): 10.
11. Bermúdez Barón N., et al. “Body mass index increase: a risk factor for forced expiratory volume in 1s decline for overweight and obese adults with asthma”. ERJ Open Research 4 (2022): 00110-2022.
12. Palma G., et al. “Adipose tissue inflammation and pulmonary dysfunction in obesity”. International Journal of Molecular Sciences 13 (2022): 7349.
13. Saha S., et al. “Effects of increased pharyngeal tissue mass due to fluid accumulation in the neck on the acoustic features of snoring sounds in men”. Journal of Clinical Sleep Medicine 10 (2018): 1653-1660.
14. Deary V., et al. “Simple Snoring: Not Quite so Simple after All?” Sleep Medicine Reviews 6 (2014): 453-462.
15. Huang L and Gao X. “The interaction of obesity and craniofacial deformity in obstructive sleep apnea”. Dentomaxillofacial Radiology 4 (2021): 20200425.
16. Ahbab S., et al. “Neck circumference, metabolic syndrome and obstructive sleep apnea syndrome evaluation of possible linkage”. Medical Science Monitor 19 (2013): 111-117.
17. Ly S., et al. “The neurobiological basis of sleep: Insights from Drosophila”. Neuroscience and Biobehavioral Reviews 87 (2018): 67-86.
18. Medic G., et al. “Short- and long-term health consequences of sleep disruption”. Nature and Science of Sleep 9 (2017): 151-161.
19. Lee ML., et al. “High risk of near-crash driving events following night-shift work”. Proceedings of the National Academy of Sciences of the United States of America 1 (2016): 176-181.
20. Watson NF., et al. “Recommended Amount of Sleep for a Healthy Adult: A Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society”. Sleep6 (2015): 843-844.
21. Dollman J., et al. “Trends in the duration of school-day sleep among 10- to 15-year-old South Australians between 1985 and 2004”. Acta Paediatrica 7 (2007): 1011-1014.
22. Luyster FS., et al. “Boards of Directors of the American Academy of Sleep Medicine and the Sleep Research Society. Sleep: a health imperative”. Sleep6 (2012): 727-734.
23. Maung SC., et al. “Sleep disorders and chronic kidney disease”. World Journal of Nephrology 3 (2016): 224-232.
24. Leproult R and Van Cauter E. “Role of sleep and sleep loss in hormonal release and metabolism”. Endocrine Development 17 (2010): 11-21.
25. NHLBI, NIH Sleep Apnea - What Is Sleep Apnea? (2022).
26. Watson NF. “Health Care Savings: The economic value of diagnostic and therapeutic care for obstructive sleep apnea”. Journal of Clinical Sleep Medicine 8 (2016): 1075-1077.
27. Benjafield AV., et al. “Estimation of the global prevalence and burden of obstructive sleep apnea: a literature-based analysis”. Lancet Respiratory Medicine 8 (2019): 687-698.
28. Yang X., et al. “Implication of mixed sleep apnea events in adult patients with obstructive sleep apnea-hypopnea syndrome”. Sleep Breath2 (2019): 559-565.
29. Chang JL., et al. “International Consensus Statement on Obstructive Sleep Apnea”. International Forum of Allergy and Rhinology 7 (2023): 1061-1482.
30. Sankri-Tarbichi AG. “Obstructive sleep apnea-hypopnea syndrome: Etiology and diagnosis”. Avicenna Journal of Medicine 1 (2012): 3-8.
31. Gottlieb DJ and Punjabi NM. “Diagnosis and management of obstructive sleep apnea a review”. Journal of the American Medical Association 14 (2020): 1389-1400.
32. Kim AM., et al. “Tongue fat and its relationship to obstructive sleep apnea”. Sleep 10 (2014): 1639-1648.
33. Reddy SS., et al. “Turbinate Dysfunction: Focus on the role of the inferior turbinates in nasal airway obstruction”. SOURCE: Grand Rounds (2014).
34. Hultcrantz E., et al. “Sleep apnea in children without hypertrophy of the tonsils”. Clinical Pediatrics (Phila)7 (1988): 350-352.
35. Wolk R., et al. “Obesity, sleep apnea, and hypertension”. Hypertension6 (2003): 1067-1074.
36. Davies RJ., et al. “Neck circumference and other clinical features in the diagnosis of the obstructive sleep apnoea syndrome”. Thorax 2 (1992): 101-105.
37. Jordan AS., et al. “Adult obstructive sleep apnea”. Lancet 9918 (2014): 736-747.
38. Eckert DJ., et al. “Mechanisms of apnea”. Progress in Cardiovascular Diseases 4 (2009): 313-323.
39. Baburao A and Souza GD. “Insulin resistance in moderate to severe obstructive sleep apnea in nondiabetics and its response to continuous positive airway pressure treatment”. North American Journal of Medicine and Science 10 (2014): 500-504.
40. Spiegel K., et al. “Sleep loss: a novel risk factor for insulin resistance and type 2 diabetes”. Journal of Applied Physiology 19855 (2005): 2008-2019.
41. Maeda T., et al. “Obstructive sleep apnea syndrome should be considered as a cause of nocturia in younger patients without other voiding symptoms”. Canadian Urological Association Journal 7-8 (2016): E241-E245.
42. Russell MB., et al. “Headache in sleep apnea syndrome: epidemiology and pathophysiology”. Cephalalgia10 (2014): 752-755.
43. Yeghiazarians Y., et al. “Obstructive sleep apnea and cardiovascular disease: A scientific statement from the American heart association”. Circulation3 (2021): e56-e67.
44. Johns MW. “A new method for measuring daytime sleepiness: the Epworth sleepiness scale”. Sleep6 (1991): 540.
45. Malhotra A., et al. “Metrics of sleep apnea severity: beyond the apnea-hypopnea index”. Sleep 7 (2021): zsab030.
46. Benjafield AV., et al. “Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis”. Lancet Respiratory Medicine 8 (2019): 687-698.
47. Jaiswal SJ., et al. “Raising awareness about sleep disorders”. Lung India3 (2017): 62-268.
48. Marin JM., et al. “Association between treated and untreated obstructive sleep apnea and risk of hypertension”. Journal of the American Medical Association 20 (2012): 2169-2176.
49. Pedrosa RP., et al. “Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension comparative study”. Hypertension5 (2011): 811-817.
50. Epstein LJ., et al. “Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults”. Journal of Clinical Sleep Medicine 3 (2009): 263-276.
51. Wozniak DR., et al. “Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea”. Cochrane Database Systematic Review 4 (2020): CD007736.
52. Hu FB., et al. “Snoring and risk of cardiovascular disease in women”. Journal of the American College of Cardiology 2 (2000): 308-313.
53. Trzepizur W., et al. “Sleep apnea-specific hypoxic burden, symptom subtypes, and risk of cardiovascular events and all-cause mortality”. American Journal of Respiratory and Critical Care Medicine 1 (2022): 108-117.
54. Xia F and Sawan M. “Clinical and research solutions to manage obstructive sleep apnea: A review”. Sensors (Basel)5 (2021): 1784.
55. Kim AM., et al. “Tongue fat and its relationship to obstructive sleep apnea”. Sleep10 (2014): 1639-1648.
56. Ng SSS., et al. “Effect of weight loss and continuous positive airway pressure on obstructive sleep apnea and metabolic profile stratified by craniofacial phenotype: a randomized clinical trial”. American Journal of Respiratory and Critical Care Medicine6 (2022): 711-720.
57. Peppered PE., et al. “Longitudinal study of moderate weight change and sleep-disordered breathing”. Journal of the American Medical Association23 (2000): 3015-3021.
58. Singh A., et al. “Epidemiologic and etiologic considerations of obesity”. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing (2024).
59. Mahmood SS., et al. “The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective”. Lancet9921 (2014): 999-1008.
60. Koliaki C., et al. “The implication of gut hormones in the regulation of energy homeostasis and their role in the pathophysiology of obesity”. Current Obesity Reports 3 (2020): 255-271.
61. Martin AM., et al. “Mechanisms controlling hormone secretion in human gut and its relevance to metabolism”. Journal of Endocrinology1 (2019): R1-R15.
62. La Barre J. “Sur les possibilités d'un traitement du diabète par l'incrétine”. Bulletin de l'Académie Royale de Médecine de Belgique (1932) 12 (2018): 620-634.
63. Takeda J., et al. “Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor”. Proceedings of the National Academy of Sciences of the United States of America20 (1987): 7005-7008.
64. Nauck MA., et al. “The evolving story of incretins (GIP and GLP-1) in metabolic and vascular disease: A pathophysiological update”. Diabetes, Obesity and Metabolism 3 (2021): 5-29.
65. Blackman A., et al. “Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial”. International Journal of Obesity (London) 8 (2016): 1310-1319.
66. Malhotra A., et al. “Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial”. Contemporary Clinical Trials 141 (2024): 107516.
67. Wang SH., et al. “Effect of weight loss on upper airway anatomy and the apnea-hypopnea index. The importance of tongue fat”. American Journal of Respiratory and Critical Care Medicine 6 (2020): 718-727.
68. McEvoy RD., et al. “CPAP for prevention of cardiovascular events in obstructive sleep apnea”. New England Journal of Medicine 10 (2016): 919-931.
69. Patel SR., et al. “Continuous positive airway pressure for treating sleepiness in a diverse population with obstructive sleep apnea: results of a meta-analysis”. Archives of Internal Medicine 5 (2003): 565-571.